What is PhaseV?
PhaseV operates at the intersection of biotechnology and artificial intelligence, specializing in the development of adaptive trial design and closed-loop execution systems. The company utilizes sophisticated algorithms, including reinforcement learning and causal machine learning, to optimize the efficiency of clinical trials. By identifying hidden signals within complex datasets, PhaseV enables researchers to extract actionable insights that significantly improve trial success rates. This technological approach addresses the industry's persistent challenges regarding resource allocation and time-to-market, establishing the company as a pivotal innovator in the clinical research landscape.
How much funding has PhaseV raised?
PhaseV has raised a total of $65M across 2 funding rounds:
Other Financing Round
$15M
Series A
$50M
Other Financing Round (2023): $15M with participation from LionBird, Exor Ventures, and Viola Ventures
Series A (2025): $50M led by EXOR, LionBird, Accel, Insight Partners, and Viola Ventures
Key Investors in PhaseV
EXOR
Exor is an investment holding company that makes medium to long-term investments across diverse sectors including technology and industrial services.
LionBird
LionBird is a venture firm focused on health-tech startups, providing pre-scale capital to teams aiming to transform the healthcare landscape.
Accel
Accel is a global venture capital firm that partners with exceptional teams from the inception of their ideas through all phases of private company growth.
What's next for PhaseV?
With the infusion of this recent capital, PhaseV is well-positioned to accelerate its product roadmap and expand its operational footprint. The company's strategic focus will likely shift toward scaling its proprietary platform to support larger, multi-center clinical trials, thereby solidifying its market position. As the firm transitions into a more mature growth phase, the emphasis will remain on enhancing its algorithmic precision and expanding its enterprise-level partnerships. Investors are closely monitoring PhaseV's ability to translate its technological advantages into sustained commercial success within the highly competitive health-tech sector.
See full PhaseV company page
